Canaccord Genuity analyst Susan Anderson maintained a Buy rating on Prestige Consumer Healthcare (PBH – Research Report) yesterday and set a price target of $79.00. The company’s shares closed last Friday at $57.88.
Anderson covers the Consumer Cyclical sector, focusing on stocks such as The Estée Lauder Companies, Ulta Beauty, and e.l.f. Beauty. According to TipRanks, Anderson has an average return of 16.8% and a 42.14% success rate on recommended stocks.
Prestige Consumer Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $79.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Prestige Consumer Healthcare’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $279.3 million and a net profit of $53.28 million. In comparison, last year the company earned a revenue of $277.02 million and had a net profit of $55.27 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
Read More on PBH:
- Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference
- Prestige Consumer reaffirms FY24 EPS view $4.27-$4.32, consensus $3.92
- Prestige Consumer reports Q1 EPS $1.06, consensus 92c
- Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2024 Results
- PBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
